EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)VergleichsstudieMultizentrische StudieRandomisierte kontrollierte Studie

Alectinib in Resected ALK -Positive Non–Small-Cell Lung Cancer

Yi-Long Wu iD, Rafal Dziadziuszko, Jin Seok Ahn, Fabrice Barlesi, Makoto Nishio, Dae Ho Lee, Jong-Seok Lee, Wenzhao Zhong, Hidehito Horinouchi, Weimin Mao, Maximilian Hochmair, Filippo de Marinis und 11 weitere

New England Journal of Medicine · 11.04.2024 · 390 (14) · 1265-1276

DOI: 10.1056/nejmoa2310532 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift New England Journal of Medicine, erschienen am 11.04.2024. Verfasst von Yi-Long Wu und 22 weiteren Autor:innen. Beteiligte Einrichtung: From the Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Tyrosine Kinase Inhibitors, Platinum Compounds. Die Arbeit wurde bisher 463-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: F. Hoffmann-La Roche Ltd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsTyrosine Kinase InhibitorsPlatinum CompoundsAntineoplastic AgentsHumansCarbazolesNeoplasm Recurrence, LocalPiperidinesReceptor Protein-Tyrosine KinasesTreatment OutcomeAdministration, OralAdministration, IntravenousAnaplastic Lymphoma Kinase

Substanzen

CarbazolesPiperidinesReceptor Protein-Tyrosine KinasesTyrosine Kinase InhibitorsPlatinum CompoundsAntineoplastic AgentsalectinibALK protein, humanAnaplastic Lymphoma Kinase

Autor:innen und Institutionen

  • From the Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou (Y.-L.W., W.Z.), the Institute of Basic Medicine and Cance…

ORCID-Profile: Yi-Long Wu

Förderung

  • F. Hoffmann-La Roche Ltd

Zitieren

APA

Wu, Y. L., Dziadziuszko, R., Ahn, J. S., Barlesi, F., Nishio, M., Lee, D. H., Lee, J. S., Zhong, W., Horinouchi, H., Mao, W., Hochmair, M., de Marinis, F., Migliorino, M. R., Bondarenko, I., Lu, S., Wang, Q., Ochi Lohmann, T., Xu, T., Cardona, A., …, & ALINA Investigators (2024). Alectinib in Resected ALK -Positive Non–Small-Cell Lung Cancer. New England Journal of Medicine, 390(14), 1265-1276. https://doi.org/10.1056/nejmoa2310532

Vancouver

Wu YL, Dziadziuszko R, Ahn JS, Barlesi F, Nishio M, Lee DH, et al. Alectinib in Resected ALK -Positive Non–Small-Cell Lung Cancer. New England Journal of Medicine. 2024;390(14):1265-1276. doi:10.1056/nejmoa2310532

BibTeX
@article{Wu2024,
  author = {Wu, Yi-Long and Dziadziuszko, Rafal and Ahn, Jin Seok and Barlesi, Fabrice and Nishio, Makoto and Lee, Dae Ho and Lee, Jong-Seok and Zhong, Wenzhao and Horinouchi, Hidehito and Mao, Weimin and Hochmair, Maximilian and de Marinis, Filippo and Migliorino, M Rita and Bondarenko, Igor and Lu, Shun and Wang, Qun and Ochi Lohmann, Tania and Xu, Tingting and Cardona, Andres and Ruf, Thorsten and Noe, Johannes and Solomon, Benjamin J and ALINA Investigators, ALINA Investigators},
  title = {Alectinib in Resected ALK -Positive Non–Small-Cell Lung Cancer},
  journal = {New England Journal of Medicine},
  year = {2024},
  volume = {390},
  number = {14},
  pages = {1265--1276},
  doi = {10.1056/nejmoa2310532}
}
Kostenlos starten →